Overview
VOLO Health uses quantitative modeling to turn diverse health data into predictive, personalized VOLO Scores that forecast 10 to 15 years of disease risk. By applying financial-market-style analytics from its sister hedge fund Voloridge Investment Management to data such as lab results, medical records, and wearables, it provides insights for proactive health decisions for individuals and clinicians. The platform also acts as an ecosystem builder and investor, offering AI-as-a-Service and Prevention-as-a-Service to corporations and health platforms, and backing health-tech innovations like AI-powered coaching. Unlike many healthcare tools, VOLO Health combines rigorous quantitative methods with long-horizon risk forecasting to unify data sources and guide long-term health planning. Its goal is to shift the industry from reactive treatment to proactive management, aiming to improve healthspan and longevity.
Work here?Claim your company
Simplify's take
What believers are saying
- VOLO Health's May 2026 Medix partnership expands corporate healthcare distribution in India.
- The June 25, 2026 clinician-training grant strengthens trust with underserved medical communities.
- Voloridge's 2026 Harbourside expansion and planned 200 jobs signal serious capital commitment.
What critics are saying
- VOLO Scores face validation risk if the 2027 Eudēmonia study disappoints.
- Voloridge Health depends on founder David Vogel and a small affiliated ecosystem in Jupiter.
- If insurers and clinicians reject 10- to 15-year risk forecasts, VOLO Health becomes a niche wellness brand.
What makes VOLO Health unique
- Voloridge Health pairs quantitative hedge-fund modeling with VOLO Scores and clinical health data.
- Its 2026 Eudēmonia study turns VOLO Scores into a visible, data-rich product demonstration.
- The company extends beyond software through investments in ONVY and Molecular You.
Help us improve and share your feedback! Did you find this helpful?